Table 1.
Demographics and health characteristics of patients who underwent RC and received either alvimopan or naloxegol.
| Naloxegol (%) | Alvimopan (%) | P value | |
|---|---|---|---|
| Male | 43 (78.2) | 59 (78.6) | 0.094β |
| Female | 12 (21.8) | 16 (21.4) | |
| Race | |||
| African American | 1 (1.8) | 3 (4) | |
| Caucasian Other |
42 (76.4) 1 (1.8) |
61 (81.3) 11 (14.7) |
0.52γ |
| Unknown | 11 (20) | 0 (0) | |
| Ethnicity | |||
| Non-Hispanic/Latino | 39 (70.9) | 71 (94.7) | |
| Hispanic/Latino | 4 (7.3) | 4 (5.3) | 0.47γ |
| Unknown | 12 (21.8) | 0 (0) | |
| Age (years) | |||
| 18–29 | 0 (0) | 1 (1.3) | |
| 30–39 | 1 (1.8) | 2 (2.7) | |
| 40–49 | 4 (7.3) | 2 (2.7) | |
| 50–59 | 12 (21.8) | 18 (24) | 0.056β |
| 60–69 | 16 (29) | 24 (32) | |
| 70–79 | 18 (32.7) | 23 (30.7) | |
| 80+ | 4 (7.3) | 5 (6.7) | |
| Smoking Status | |||
| Smoker | 7 (12.7) | 11 (14.7) | |
| Non-smoker | 19 (34.6) | 20 (26.6) | 0.64β |
| Former | 29 (52.7) | 44 (58.7) | |
| BMI | |||
| <18.5 | 1 (1.8) | 1 (1.3) | |
| 18.5–24.9 25–29.9 |
15 (27.3) 20 (36.4) |
25 (33.3) 36 (48) |
0.36β |
| > 30 | 19 (34.5) | 13 (17.3) | |
| Tumor Stage | |||
| ..0 | 5 (9.1) | 0 (0) | |
| CIS I II |
3 (5.5) 6 (10.9) 13 (23.6) |
5 (6.7) 17 (22.7) 31 (41.3) |
0.41β |
| III | 15 (27.3) | 16 (21.3) | |
| IV | 13 (23.6) | 6 (8) | |
| Co-morbidities | |||
| DM | 9 (16.4) | 14 (18.6) | |
| CVD | 8 (14.5) | 15 (20) | 0.378γ |
| GERD | 19 (34.6) | 31 (41.3) | |
β
Generalized Estimating Equation;
γ
Independent Fisher Exact Test